Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Net Cash Flow (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Net Cash Flow for 2 consecutive years, with -$25.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 11.88% to -$25.8 million in Q4 2025 year-over-year; TTM through Oct 2025 was $98.5 million, a 59.4% increase, with the full-year FY2025 number at $229.3 million, up 3503.26% from a year prior.
  • Net Cash Flow was -$25.8 million for Q4 2025 at Kestra Medical Technologies, up from -$36.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $183.2 million in Q2 2025 to a low of -$36.4 million in Q3 2025.